Peptide API manufacturing capacity: what a major CDMO acquisition signals for the research supply chain

Summary. The main acceptance period for Samsung Biologics' all-cash offer to acquire PolyPeptide Group, a Swiss contract manufacturer of peptide active ingredients, is scheduled to close on 12 October 2026. The offer values the company at about CHF 1.46 billion. Its largest shareholder has committed to tender, and completion is targeted for the end of 2026. PolyPeptide runs six cGMP sites in Belgium, France, Sweden, the United States and India. The report notes that metabolic peptides, largely incretin-class compounds, now make up most of PolyPeptide's revenue. It also says new large-scale solid-phase peptide synthesis (SPPS) capacity typically takes 18 to 36 months to bring online.

Research context (RUO). For laboratories, the story is about capacity. Large-scale SPPS, purification and lyophilisation lines are scarce, and commercial programmes compete for them. The report suggests that small-batch and development-scale buyers may want to confirm continuity terms with suppliers as ownership consolidates. More broadly, manufacturing capacity remains one of the main constraints on access to well-characterised research-grade peptide material, along with documentation such as certificates of analysis and impurity profiles.